Price
$366.44+32.87%1Y
1M+3.58%1Y+32.87%
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above average7/10
Value44
Quality93
Momentum44
Growth39
P/E (TTM)24.3
Market Cap$182.21B
1Y Return+32.87%
5Y Return+71.70%
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $6.17B (-13.92%)
●UPLIZNA grew +200.00% YoY●Enbrel -37.70% YoY
SegmentLatestQoQYoY
- Other Products$1.13B-19.67%+1.98%
- Repathaevolocumab$465.0M+5.20%+35.57%
- Prolia$461.0M-42.80%-35.97%
- EVENITY$431.0M+3.36%+34.69%
- TEPEZZA$424.0M-18.15%+16.16%
- Product And Service Other$400.0M-4.76%+44.93%
- Otezla$352.0M-25.58%+2.62%
- TEZSPIRE$343.0M-9.02%+20.35%
- Enbrel$314.0M-45.30%-37.70%
- Nplate$283.0M-15.02%+40.80%
- KRYSTEXXA$255.0M-20.31%+8.05%
- UPLIZNA$246.0M-+200.00%
- Xgeva$228.0M-36.13%-36.67%
- BLINCYTO$221.0M-6.36%-19.05%
- Kyprolis$218.0M-3.11%+0.93%
- IMDELLTRAIMDYLLTRA$188.0M-+137.97%
- Vectibix$136.0M-16.05%+0.74%
- Aranesp$77.0M-25.24%-15.38%
- Neulasta---